View Document Preview and Link Document Date: 2011-09-14 11:09:12 Open Document File Size: 115,54 KB Share Result on Facebook
Company British Medical Journal / / Country Germany / United Kingdom / / Facility German Institute / / IndustryTerm treatment of depressive illness / healthcare professionals / treatment of depression / particular patient / health technology assessments / / MedicalCondition Hamilton depression / insomnia / mild/moderate depression / disease / headache / nausea / severe clinical depression / depressive illness/major depression / clinical mental health disorder / patient’s depression / severe depression / illness / depression / moderate depression / hypotension / / Organization European Medicines Agency / MHRA / Committee for Medicinal Products for Human Use / Institut für Qualität / Medicines and Healthcare products Regulatory Agency / European Pharmacovigilance Working Party / German Institute for Quality and Efficiency / / Position Major / General / / Product mirtazapine / fluoxetine / BACKGROUND Reboxetine / / PublishedMedium the British Medical Journal / the European review / / SocialTag 
MHRA UK PUBLIC ASSESSMENT REPORT Reboxetine: a review of the benefits and risks September 2011 Plain-language summary